Unblinded: The Start-Up That Launched a Revolution in Saving Sight - Guyer; Keldoulis, Ian
22,99 €
inkl. MwSt.
Versandkostenfrei*
Erscheint vorauss. 3. Februar 2026
Melden Sie sich für den Produktalarm an, um über die Verfügbarkeit des Produkts informiert zu werden.

payback
11 °P sammeln
  • Gebundenes Buch

A life-altering revolution has happened right before your eyes. Yet for a generation, it has been largely invisible. Unblinded is the never-before-heard origin story of intravitreal, anti-VEGF therapies for macular degeneration, and other retinal diseases, and the start-up company that changed the future of eyecare. In the 1990s, age-related macular degeneration (AMD) was the leading cause of blindness in the developed world, with no effective treatments. The disease became known for robbing its elderly victims of their central vision and the opportunity to age gracefully, leaving them with…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
A life-altering revolution has happened right before your eyes. Yet for a generation, it has been largely invisible. Unblinded is the never-before-heard origin story of intravitreal, anti-VEGF therapies for macular degeneration, and other retinal diseases, and the start-up company that changed the future of eyecare. In the 1990s, age-related macular degeneration (AMD) was the leading cause of blindness in the developed world, with no effective treatments. The disease became known for robbing its elderly victims of their central vision and the opportunity to age gracefully, leaving them with the fear of going blind. Today, this is no longer the case for most people. >$15bn of revenue in one of the highest billed procedures on Medicare. In Unblinded, you'll discover how a trio of doctors stepped out of their comfort zones into a world where groundbreaking biotechnology tussles with multimillion-dollar risk-taking--often amid financial market turmoil. Despite the turbulence of their journey, David, Samir, Tony, and their many contemporaries have never taken their eyes off the ultimate prize--improving sight. Proceeds from the book go to the non-profit, Wise Eyes Foundation, with a mission to reduce the unmet need in large population retinal diseases through research and patient support.
Autorenporträt
DAVID R. GUYER, MD David is a retina specialist, a highly successful serial entrepreneur, and has been CEO of multiple public and private companies. He has seen vision research from the perspectives of academia, biotech, venture capital, and Big Pharma. David has cofounded three biotech companies-- Eyetech, Ophthotech (later known as Iveric Bio), and EyeBio, leading them all as CEO. All three have been successfully acquired, with two of the companies completing huge IPOs. David currently serves as the CEO and president of EyeBio, now a subsidiary of Merck & Co., Inc. When he is not exploring potential new retinal therapies or starting or running new companies, David enjoys working out and has run five marathons. An avid traveler, he has been to all 50 states in the US and approximately 100 countries where he often seeks exciting culinary experiences--especially extremely spicy foods--which he loves to share with his wife Maria and two sons, Luca and Oliver.